You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!
Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Foster City, California
52 Week High
52 Week Low
BRIEF-Gilead Announces Expiration Of Hart-Scott-Rodino Waiting Period For Forty Seven Tender Offer
March 30 (Reuters) - Gilead Sciences Inc: * GILEAD ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR FORTY SEVEN TENDER OFFER * GILEAD SCIENCES INC
Gilead pauses access to experimental COVID-19 drug due to 'overwhelming demand'
A close up of a test kit for testing for the coronavirus, Covid-19 is seen at Newton-Wellesley Hospital in Newton, Massachusetts on March 18, 2020, as the hospi
— per share
Expected Apr 30, After Hours
Financial TimesMar 26
The global hunt for a coronavirus drug | Free to read
It was Friday March 13 when doctors at Northwell Health, the largest healthcare provider in New York City, decided to take the search for a coronavirus drug int
New York TimesMar 25
Gilead Asks FDA to Take Back Lucrative Orphan Drug Status on Possible Coronavirus Treatment
(Reuters) - Gilead Sciences Inc on Wednesday took the unusual step of asking the U.S. Food and Drug Administration to rescind a controversial orphan drug design
Gilead asks FDA to revoke orphan drug status for potential coronavirus drug
March 25 (Reuters) - Gilead Sciences Inc said on Wednesday it had requested the U.S. Food and Drug administration to rescind the “orphan drug” status for its ex
BRIEF-Gilead Says Submitted Request To FDA To Waive All Benefits That Accompany Orphan Drug Designation
March 25 (Reuters) - Gilead Sciences Inc: * GILEAD SCIENCES SAYS SUBMITTED REQUEST TO U.S. FDA TO RESCIND ORPHAN DRUG DESIGNATION GRANTED FOR INVESTIGATIONAL A